Last updated: June 4, 2026
ISOVUE-128 is the 100 mL and 200 mL intravenous injection form of ioversol (a non-ionic, iodinated contrast agent). Supply for ISOVUE-128 is primarily tied to the contract manufacturer that produces ioversol injection for Bracco, plus channel partners (wholesalers and distributors) that hold National Drug Code (NDC) distribution rights in the US.
Who supplies ISOVUE-128 in the US market?
Answer: ISOVUE-128 is supplied by Bracco (brand holder) through its distribution network, using the approved manufacturing site(s) listed for the ioversol injection product in FDA submissions and the corresponding NDC labeling. Day-to-day “suppliers” to hospitals and imaging centers are typically US pharmaceutical wholesalers and specialty distributors, sourced from Bracco’s authorized supply chain.
What is the role of Bracco in ISOVUE-128 supply?
Bracco is the US brand owner and controls product labeling, QA release strategy, and distribution authorizations tied to specific NDC presentations. ISOVUE-128 supply is therefore administered through Bracco’s commercial and regulatory system, while physical drug supply comes from listed finished-dose manufacturing sites.
What counts as an ISOVUE-128 “supplier”?
For procurement and continuity planning, the relevant supplier set is usually:
- Contract manufacturer(s) producing ioversol injection finished product
- Bracco’s NDC-labeled supply released into the US distribution chain
- Authorized wholesalers and distributors supplying hospitals, group purchasing organizations (GPOs), and imaging centers
What NDC coverage does procurement need to confirm?
ISOVUE-128 is offered in multiple container sizes (commonly 100 mL and 200 mL glass vial presentations). Buyer controls must be locked to the exact NDC, because distributor availability can differ by presentation even when the active ingredient is the same (ioversol) and the concentration is identical.
Which companies make ioversol injection used for ISOVUE-128?
Answer: ioversol injection is manufactured at one or more FDA-registered sites under Bracco’s product license. The specific manufacturer name(s) and site addresses are determined by the FDA listing for the ISOVUE-128 NDC(s) (labeler/manufacturer section).
How to map “manufacturer” vs “labeler” for ISOVUE-128
- Labeler: the company that appears on the NDC as responsible for the drug product labeling (typically Bracco).
- Manufacturer: the contract manufacturing/finished dose site that produces under the approved application and holds manufacturing authorization.
Why this matters for supplier qualification
Hospital supply chains qualify based on:
- cGMP compliance and FDA inspection history of the manufacturing site
- lot-to-lot variability controls
- ability to support tender volumes across multiple vial sizes
- cold-chain requirements (for iodinated contrasts, storage is usually controlled room temperature, but procurement should verify label specifics)
What distributors supply ISOVUE-128 to hospitals and imaging centers?
Answer: ISOVUE-128 is distributed through major US pharmaceutical wholesalers and distribution channels that carry branded sterile injectables, sourced from Bracco’s NDC-labeled inventory. The practical “supplier” for end users is usually the wholesaler fulfilling purchase orders, not the contract manufacturer.
Typical distributor categories for ISOVUE-128
- National pharmaceutical wholesalers (direct ship or warehouse replenishment)
- Specialty distributors for injectables/sterile products
- GPO-channel intermediaries where tender pricing routes through contracted distributors
How to structure distributor due diligence
Procurement teams typically verify:
- On-hand and lead time by NDC and vial size
- allocation risk during shortage events
- return policies, lot traceability, and expiration management
- ability to provide CoC and documentation tied to lot numbers
Does ISOVUE-128 have a biosimilar or generic “supplier” risk?
Answer: ISOVUE-128 is a small-molecule iodinated contrast agent, not a biologic. Supply risk is not “biosimilar” driven; it is driven by sterile manufacturing capacity, procurement cycles, and any regulatory or quality events affecting the ioversol injection supply chain.
What replaces ISOVUE-128 when supply tightens?
In the event of supply constraints, hospitals typically substitute among the iodinated contrast portfolio (same therapeutic class, different active ingredient) per radiology protocols. Substitute selection is typically governed by allergy history, dosing, and image-quality needs, not IP.
How do you confirm ISOVUE-128 supplier authority for contracting?
Answer: Contracting should tie each purchased presentation to the exact NDC and confirm that the distributor is sourcing from the authorized channel and providing lot traceability documentation.
Key procurement artifacts
- NDC-specific product label matching
- lot number traceability to Certificate of Analysis
- documentation showing source channel compliance (authorized distribution chain)
- confirmation of expiry and storage conditions per label
ISOVUE-128 supply timeline and availability drivers
Answer: Availability is driven by manufacturing batch schedules for sterile ioversol injection, plus FDA and quality release capacity at the manufacturing site(s). External disruptions that can affect sterile injectable supply include:
- raw material availability for iodinated intermediates
- packaging glass vial availability
- sterile filling line uptime and changeover schedules
- batch disposition and QA release timing
What procurement teams monitor
- Bracco’s public supply communications (when issued)
- distributor allocation announcements
- lead-time changes by NDC presentation
- lot expiries and shelf-life coverage for large customer orders
Key comparisons: ISOVUE-128 vs alternative iodinated contrast suppliers
Answer: ISOVUE-128 is one product within a competitive set of non-ionic iodinated contrast agents supplied by multiple manufacturers. Substitution options can reduce dependence on a single brand supply chain.
Competitive substitute framework for procurement
When substituting, buyers typically compare:
- concentration and iodine delivery per mL
- osmolality and viscosity profile
- injection mechanism compatibility (rate capability)
- packaging format (vial vs syringe, size availability)
- distributor availability by NDC
Key Takeaways
- ISOVUE-128 supply is controlled by Bracco as the labeler/brand owner and executed through FDA-listed ioversol injection manufacturing sites plus Bracco’s authorized distribution network.
- End-user procurement is usually fulfilled by major pharmaceutical wholesalers and specialty distributors carrying Bracco branded sterile injectables.
- Supplier qualification for continuity planning should be NDC-specific (including vial size) and must include lot traceability and documentation tied to the purchased presentation.
- Generic or biosimilar substitution is not the main risk category; the main supply risk is sterile manufacturing capacity and QA release timing.
FAQs
-
How do I identify the exact ISOVUE-128 NDC for a tender?
Match the product presentation (vial size) to the NDC printed on packaging and purchase specifications, then verify that the distributor invoice NDC matches the tender NDC.
-
Who is the labeler for ISOVUE-128 on the NDC directory?
The labeler appears in the NDC listing for the ISOVUE-128 ioversol injection presentations and typically aligns with Bracco’s regulatory/marketing responsibility.
-
What documents should hospitals require from distributors for ISOVUE-128 lots?
Certificates of Analysis for the specific lot, lot traceability documentation, and shipping/storage compliance records consistent with the product label.
-
What is the most common reason ISOVUE-128 becomes unavailable?
Sterile manufacturing and release capacity constraints at the manufacturing site(s) supporting ioversol injection, often coupled with packaging or raw material supply chain friction.
-
What are the procurement best practices when switching from ISOVUE-128 during supply shortages?
Switch by NDC-compatible therapeutic equivalence within the iodinated non-ionic contrast class, after confirming clinical protocol alignment (dosing, rate, iodine delivery) and verifying distributor availability by presentation.
References
- FDA. NDC Directory. (Product and labeling information for ioversol injection, ISOVUE-128 presentations).
- FDA. Drug Shortages database. (If applicable communications for iodinated contrast products and ioversol supply status).
